Investors

BERKELEY HEIGHTS, N.J., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer biology, announced that data from Cyclacel’s CYC065 and sapacitabine ongoing clinical studies have been selected for presentation at the 61^stAmerican Society of Hematology Annual Meeting and Exposition (December 7-11) in Orlando, Florida. The poster presentations will provide details and updates for three clinical studies: CYC065 in combination with venetoclax in patients with relapsed or refractory CLL, CYC065 in combination with venetoclax in patients with relapsed or refractory AML or MDS and sapacitabine in combination with venetoclax in patients with relapsed or refractory AML or MDS. All three trials are being conducted as part of Cyclacel’s collaboration with MD Anderson Cancer Center.

Presentation details are as follows:

Title: A Phase I Study Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Presenter: Dr. William G. Wierda
Session Name: 642. CLL: Therapy, excluding Transplantation: Poster I
Date: Saturday, December 7, 2019
Presentation Time: 5:30 PM - 7:30 PM
Location: Orange County Convention Center, Hall B
Publication Number: 1761

Title: Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Patients with Relapsed or Refractory AML or MDS
Presenter: Dr. Gautam Borthakur
Session Name: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster I
Date: Saturday, December 7, 2019
Presentation Time: 5:30 PM - 7:30 PM
Location: Orange County Convention Center, Hall B
Publication Number: 1379

Title: An Oral Combination Study of Novel Nucleoside Analogue Sapacitabine and BCL2 Inhibitor Venetoclax to Treat Patients with Relapsed or Refractory AML or MDS
Presenter: Dr. Tapan Kadia
Session Name: Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III
Date: Monday, December 9, 2019
Presentation Time: 6:00 PM - 8:00 PM
Location: Orange County Convention Center, Hall B
Publication Number: 3926

In addition researchers from Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom led by Professor Mhairi Copeland will present preclinical data on the combination of CY065 and venetoclax.

Title: Combination of CYC065, a Second Generation CDK2/9 Inhibitor, with Venetoclax or Standard Chemotherapies – a Novel Therapeutic Approach for Acute Myeloid Leukaemia (AML)
Presenter: Dr. Wittawat Chantkran
Session Name: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III
Date: Monday, December 9, 2019
Presentation Time: 6:00 PM - 8:00 PM
Location: Orange County Convention Center, Hall B
Publication Number: 3938

Abstracts for the 2019 ASH Annual Meeting can be accessed at: https://www.hematology.org/Annual-Meeting/.

About Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation and DNA damage response biology. The transcriptional regulation program is evaluating CYC065 as a single agent in solid tumors and in combination with venetoclax in patients with relapsed or refractory CLL and AML/MDS. The DNA damage response program is evaluating an oral combination regimen of sapacitabine and venetoclax in patients with relapsed or refractory AML/MDS. An IST is evaluating an oral combination regimen of sapacitabine and olaparib in patients with BRCA mutant breast cancer. The anti-mitotic program is evaluating CYC140, a PLK1 inhibitor, in AML/MDS patients. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a pipeline of novel drug candidates. For additional information, please visit www.cyclacel.com.

Forward-looking Statements
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and intended utilization of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and other filings we file with the Securities and Exchange Commission and are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

© Copyright 2019 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel^® are trademarks of Cyclacel Pharmaceuticals, Inc.